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Abstract
Objectives: To summarize data supporting the effects of antidiabetes agents on glucose control and
cardiovascular risk factors in patients with type 2 diabetes.
Methods: Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels,
and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic
regimens for patients with type 2 diabetes.
Results: National guidelines recommend the aggressive management of cardiovascular risk factors in patients with
type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes
pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While
thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are
considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-
like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally,
metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial
effects on lipid and blood pressure parameters.
Conclusion: Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a
multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to
improve and/or correct the underlying cardiovascular risk factors.
Introduction
Type 2 diabetes is an increasingly prevalent, complex
disease associated with a high risk of morbidity and
mortality due to cardiovascular disease (CVD). Approxi-
mately 23.6 million Americans have diabetes, with up to
95% having type 2 diabetes [1]. Numerous clinical stu-
dies have shown a direct relationship between the level
of hyperglycemia and CVD morbidity and mortality.
CVD in patients with diabetes includes coronary artery
disease, peripheral vascular disease, cerebrovascular dis-
ease, diabetic cardiomyopathy, and hypertensive cardio-
myopathy [2-5]. A prospective, observational study
found a significant relationship between various degrees
of hyperglycemia and both microvascular and macrovas-
cular end points, including myocardial infarction (MI)
and all-cause mortality (p < 0.0001 for all). Additionally,
it has been reported that each 1.0% reduction in gly-
cated hemoglobin (HbA1c) is associated with a 14%
reduction in the incidence of MI (p < 0.0001) [6].
However, conflicting findings in large-scale clinical
trials involving more than 21,000 patients on the effects
of intensive glucose control with aggressive HbA1c goals
on CVD events has been a topic of much debate [7].
Two recently published meta analyses of randomized
clinical trials reported that intensive glucose control is
associated with reductions in CVD events but has no
significant effect on CVD death or all-cause mortality.
Intensive glucose lowering was associated with a 16-17%
reduction in nonfatal MI and an 11-15% reduction in
coronary heart disease (CHD) (p < 0.05, for all) [8,9].
Diabetes is a powerful risk factor for the development
of atherosclerosis and associated CVD. Patients with
diabetes have a 2- to 4-fold higher risk of CVD death
compared with patients without diabetes; approximately
65% of deaths in patients with diabetes, of which type 2
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more likely to develop at a younger age in patients with
diabetes than patients without diabetes with increasing
risk over the duration of the disease [3]. While pre-
menopausal women without diabetes traditionally lag
behind men in CVD by approximately 10 years due to
the protective effects of estrogen, this benefit is lost by
the development of diabetes. The risk of MI in a mid-
dle-aged patient with diabetes and no prior MI is the
same as that of a patient with a prior MI but no dia-
betes. Therefore, patients with diabetes are considered
to be at high risk for CHD events, equivalent to the risk
seen in patients with documented vascular disease
[3,10].
The risk of developing CVD is elevated even in those
with prediabetes and/or the cardiometabolic syndrome
that exhibit impaired fasting glucose (IFG) and/or
impaired glucose tolerance (IGT). The approximate
annualized risk of nonfatal CV events per 100 patients
with IGT or IFG has been estimated at 11.6 to 12.4 and
0.63 to 9.70, respectively [11,12]. Furthermore, the risk of
developing CVD dramatically increases when both
diabetes and overweight/obesity are present. The coexis-
tence of these 2 comorbidities results in a lifetime risk of
between 80% and 90% of development of CVD in women
and men, respectively [13]. Nearly 85% of patients with
type 2 diabetes are overweight (body mass index [BMI]
≥ 25 kg/m
2) and approximately 55% are considered obese
(BMI ≥ 30 kg/m
2) [14]. Weight gain and obesity are vital
factors in the increasing prevalence of both type 2 dia-
betes and CVD [14-16]. An analysis of overweight/obese
patients with type 2 diabetes (N = 4,916) and baseline
BMI 25-40 kg/m
2 showed a 13% increased risk of fatal
and nonfatal CHD for every 1-unit increase in BMI over
a mean 5.6-year follow-up [17].
Implementation of strategies to prevent the develop-
ment of overt CVD could result in the reduction of a
large number of clinical CVD events. Using the Archi-
medes Model, 11 prevention activities relating to CVD
were evaluated to determine their impact on morbidity
and mortality. The model was applicable to 156 million
Americans, between 20 and 80 years of age, who met
the criteria for implementation of CVD prevention stra-
t e g i e s ,s u c ha sw e i g h tl o s s ,b l o o dp r e s s u r e( B P )c o n t r o l ,
and management of dyslipidemia. If everyone adopted
the prevention strategies as outlined, approximately 221
million life-years and 244 million quality-adjusted life-
years could be added to adults in the United States over
the next 30 years [18]. Due to the strong relationship
between type 2 diabetes and CVD, as well as the related
morbidity and mortality, optimizing the care of patients
with type 2 diabetes and CVD must be a shared respon-
sibility among cardiologists, diabetologists, and primary
care physicians, and should include screening for CV
risk factors. Throughout the management of patients
with type 2 diabetes, strategies should be implemented
to improve the CV risk profile [19], including glucose
control, which leads to a delay or prevention of vascular
complications [6], weight loss, smoking cessation, and
management of hypertension and dyslipidemia. Never-
theless, at this time, no specific antiglycemic treatment
modality has been shown to lower the incidence of
CVD in long-term outcomes trials.
This paper will examine the relationship between type
2 diabetes and CVD, with an emphasis on the effects of
antidiabetes agents on glucose lowering and other CVD-
associated risk factors, including weight, lipids, BP, pro-
thrombotic factors (e.g fibrinogen) and inflammatory
markers (e.g. high-sensitivity C-reactive protein
[hs-CRP]).
Risk Factors, Lifestyle Interventions, and Treatment
Guidelines
The non-modifiable and modifiable risk factors for type
2 diabetes and CVD are presented in table 1[10,20].
A joint scientific statement of the American Diabetes
Association (ADA) and European Association for the
Study of Diabetes (EASD) advocates lifestyle manage-
ment, including diet and exercise, as the initial treat-
ment approach for the prevention and/or management
of type 2 diabetes morbidity and mortality, as well as
throughout all stages of type 2 diabetes management,
with the goal of weight loss and improvement of modifi-
able risk factors [21]. Specific dietary recommendations
include limiting saturated and trans fat and alcohol
intake, monitoring carbohydrate consumption, and
increasing dietary fiber. In addition, patients with type 2
diabetes should perform 150 minutes of moderate to
vigorous aerobic exercise each week and, in the absence
of contraindications, engage in resistance training
3 times a week [20,22].
Even small weight reductions have been shown to
have significant beneficial effects. A weight loss of
5-10% of initial body weight has lowered the risk for
diabetes and CVD, as well as significant (p = 0.001)
improvements in related modifiable risk factors, includ-
ing HbA1c, high-density lipoprotein cholesterol (HDL-
C), triglycerides (TGs), systolic blood pressure (SBP),
and diastolic blood pressure (DBP) [23]. In a meta-
analysis of 9 studies including 162 obese patients with
type 2 diabetes, a modest 9.6% reduction in initial body
weight over 6 weeks was associated with a decrease in
fasting plasma glucose concentrations to < 50% of initial
values [16].
Both the American Association of Clinical Endocrinol-
ogists (AACE)/American College of Endocrinology
(ACE) and ADA have established practice guidelines
(with slight differences in goals) outlining target glucose,
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Additionally, treatment algorithms have been developed
by the ADA/(EASD) and AACE/ACE [24] for the man-
agement of patients with type 2 diabetes (figure 1) [21],
outlining step-wise recommendations for treatment
initiation and alterations based on HbA1c-lowering effi-
cacy, additive effects, and costs associated with interven-
tions [22]. The new AACE/ACE algorithms also
prioritize regimens based on their ability to minimize
the risk and severity of hypoglycemia and the risk and
magnitude of weight gain. Thus, these algorithms favor
the use of glucagon-like peptide-1 (GLP-1) receptor ago-
nists and dipeptidyl peptidase-4 (DPP-4) inhibitors
because of their efficacy and safety, include thiazolidine-
diones (TZDs) as “well-validated” agents, and move sul-
fonylureas (SFUs) to lower priority because of their risk
of hypoglycemia, weight gain, and short period of effi-
cacy [24]. At all steps, lifestyle interventions are recom-
mended and should be encouraged [21]. The effects of
specific agents on modifiable risk factors and the CV
risk profile should also be considered when building an
antidiabetes regimen.
Following are a review of the effects of the various
antidiabetic agents on glycemic control, body weight,
and other CV risk factors, e.g. serum lipids, BP, pro-
thrombotic factors, and inflammatory markers. While
glycemic control is important in reducing a patient’s
overall CV risk, lipid treatment with statins, manage-
ment of hypertension, and weight loss have been shown
to be more important than just glucose control in redu-
cing CV risk in patients with type 2 diabetes.
The Effects of Antidiabetes Agents on Glycemic Control
In reviewing the effects of antidiabetic agents on glyce-
mic control, it must be noted that clinical studies may
have differences in design, as well as baseline patient
characteristics, which may affect results. For example,
lower baseline glycemia may reduce the apparent glu-
cose-lowering efficacy of antidiabetic agents. Thus, com-
parisons of newer agents to older ones is particularly
difficult as patients entering more recent clinical trials
typically have lower HbA1c than previous studies and
do not usually go through a “washout period” prior to
drug initiation [25,26]. For the purpose of this paper,
individual end points will be analyzed separately and
focus more on efficacy than safety parameters.
Data from large-scale clinical trials, including the
United Kingdom Prospective Diabetes Study (UKPDS 33,
Table 1 Modifiable and non-modifiable risk factors associated with type 2 diabetes mellitus and cardiovascular
disease [10,20]
Modifiable Risk Factors Non-modifiable Risk Factors
Overweight/obesity Family history of diabetes or premature CHD
Sedentary lifestyle Cardiovascular disease
Cigarette smoking Latino/Hispanic, Non-Hispanic black, Asian American, Native American, or Pacific Islander
ethnicity
Hypertension History of gestational diabetes
Increased LDL-C and/or triglycerides and/or low
HDL-C
History of delivery of infant with birth weight >9 pounds
Psychiatric illness Polycystic ovary syndrome
IGT or IFG Age
CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density
lipoprotein cholesterol.
Table 2 Comparison of guidelines for the management of patients with type 2 diabetes mellitus [20,22]
HbA1c Fasting Glucose Postprandial Glucose Blood
Pressure
Lipids
AACE/ACE,
2007 [20]
≤ 6.5% Fasting plasma glucose < 110
mg/dL
2-hr postprandial glucose < 140
mg/dL
< 130/80
mmHg
LDL-C < 100 mg/dL
(< 70 mg/dL for patients with DM
and coronary artery disease)
HDL-C >40 mg/dL in men, > 50 mg/
dL in women
Triglycerides < 150 mg/dL
ADA, 2009
[22]
< 7.0% Preprandial capillary plasma
glucose, 70-130 mg/dL
Peak postprandial capillary plasma
glucose < 180 mg/dL
< 130/80
mmHg
LDL-C < 100 mg/dL*
HDL-C >40 mg/dL in men, > 50 mg/
dL in women
Triglycerides < 150 mg/dL
*In individuals with overt cardiovascular disease, a lower LDL-C goal of < 70 mg/dL (1.8 mmol/L), using high doses of a statin, is an option.
AACE, American Association of Clinical Endocrinologists; ACE, American College of Endocrinology; ADA, American Diabetes Association; DM, diabetes mellitus;
HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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improves morbidity and mortality in patients with type 2
diabetes. In UKPDS 33, patients randomized to intensive
therapy (n = 2,729) had lower HbA1c concentrations
compared with patients treated with conventional ther-
apy (n = 1,138) over 10 years of follow-up and experi-
enced a lower rate of diabetes-related end points,
including a significant 25% r e d u c t i o ni nm i c r o v a s c u l a r
complications (p = 0.0099) [27]. Likewise, UKPDS 75
found that each 1.0% decrement in HbA1c was associated
with a 21% risk reduction in any diabetes-related end
point, a 22% reduction in diabetes-related death, and a
14% reduction in all-cause mortality (p < 0.0001 for all)
[28]. Furthermore, although differences between HbA1c
concentrations were lost after 1 year, the effects of inten-
sive therapy (n = 2,729) versus conventional therapy (n =
1,138) in patients with type 2 diabetes in UKPDS 80
translated into a significant reduction in any diabetes-
related end point (9%, p = 0.04), microvascular disease
(24%, p = 0.001), diabetes-related death (17%, p = 0.01),
and all-cause mortality (13%, p = 0.007) at 10 years [29].
While all currently available antidiabetes agents lower
glucose and HbA1c, the magnitude of reduction is vari-
able (table 3) [20,21,25,30-35].
Sulfonylureas (SFU)
SFUs lower glucose levels and HbA1c by increasing the
secretion of insulin from pancreatic beta-cells, resulting
in reduced HbA1c by approximately -0.9% to -2.5%.
SFUs are approved for use as monotherapy, as well as in
combination with other antidiabetes agents, with the
exception of glinides, and insulin. Optimal therapeutic
benefits with sulfonylureas are seen at approximately
half the maximum dose [20-22].
Glinides
Similar to SFUs, glinides stimulate the secretion of insu-
lin; however, because glinides have a shorter half-life,
they result in a rapid, short-lived release of insulin for
up to 2 hours, thus requiring frequent dosing. The 2
currently available glinides, repaglinide and nateglinide,
r e d u c eH b A 1 cu pt o- 1 . 9 %f r o mb a s e l i n ea n dm a yb e
used as monotherapy or in combination [20,21,33].
Biguanides
Metformin (MET) lowers hyperglycemia by reducing
hepatic gluconeogenesis in t h ep r e s e n c eo fi n s u l i na n d
improving insulin sensitivity by increasing peripheral glu-
cose uptake and utilization [20,21,36]. As monotherapy,
MET has been associated with reductions in A1C of -1.1%
to -3.0% [20]. MET is also approved for use in combina-
tion with SFUs, TZDs, insulin [20], and sitagliptin [21].
Thiazolidinediones
TZDs affect glucose metabolism in both the liver and per-
iphery through multiple pathways. TZDs are insulin sensi-
tizers and lower glucose by improving the response of
target cells to insulin. They also promote adipocyte differ-
entiation, which results in more cells with higher insulin
sensitivity, and the expression and translocation of the glu-
cose transporter, GLUT-4, which increases glucose uptake
in the presence of insulin [21,37]. The 2 available TZDs,
pioglitazone and rosiglitazone, are approved for use in
combination with MET, SFUs, glinides, and insulin. These
drugs have been shown to produce similar reductions in
HbA1c of approximately -1.6%, with reductions ranging
from -1.2% to -2.3% over 3-12 months of therapy
[20,21,38-41].
Insulin
Insulin regulates the metabolism of carbohydrates, pro-
tein, and fat by acting on specific membrane-bound
receptors on target tissues and facilitating glucose
uptake into muscle, adipose, and other tissues [20,36].
Insulin therapy provides the greatest glucose-lowering
effects and has been associated with reductions in
HbA1c of up to -4.9% when used in combination with
MET [21,34]. However, the initiation of insulin therapy
is often delayed until the later stages of disease after
initial treatment failure due to concerns regarding
weight gain, hypoglycemia, and convenience [34].
Glucagon-like peptide-1 receptor agonists
GLP-1 receptor agonists are part of a new class of
agents, the incretin mimetics, which provide reductions
in HbA1c ranging from -0.8% to -1.5%. GLP-1 receptor
agonists have many of the effects seen with native GLP-
1 in the regulation of glucose metabolism including
stimulating insulin production and response during peri-
ods of elevated blood glucose, inhibiting glucagon
release, slowing nutrient absorption, and increasing feel-
ings of satiety [20]. Exenatide is the first US Food and
Drug Administration (FDA)-approved agent in this class
for the treatment of patients with type 2 diabetes. It is
approved as monotherapy as an adjunct to diet and
exercise to improve glycemic control in adults with type
2 diabetes, and is also indicated in combination with
At diagnosis:
Lifestyle
+ Metformin
Lifestyle + Metformin
+ Intensive insulin
Lifestyle + Metformin
+ Basal insulin
Lifestyle + Metformin
+ Sulfonylurea*
Lifestyle + Metformin
+ Pioglitazone
Tier 1: Well-validated 
core therapies
Tier 2: Less well-
validated 
therapies
STEP 1 STEP 2 STEP 3
Lifestyle + Metformin
+ GLP-1 receptor
agonist†
Lifestyle + Metformin
+ Basal insulin
Lifestyle + Metformin
+ Pioglitazone
+ Sulfonylurea*
Figure 1 American Diabetes Association/European Association
for the Study of Diabetes consensus guidelines treatment
algorithm for patients with type 2 diabetes mellitus.
*Sulfonylureas other than glyburide or chlorpropamide.
† Insufficient
clinical use to be confident regarding safety. GLP-1, glucagon like
peptide-1. Reprinted with permission from Nathan et al (2009) [21].
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without MET [20]. Liraglutide, a once-daily GLP-1
receptor agonist was recently approved by the US FDA.
It is indicated as an adjunct to diet and exercise to
improve glycemic control in patients with type 2 dia-
betes. It is not recommended as first-line therapy. A
once-weekly formulation of exenatide has been sub-
mitted to the US FDA for regulatory review. Exenatide
lowers glucose concentrations and HbA1c by approxi-
mately -1.0% with reductions of -0.8% to -0.9% at 30
weeks and -1.0% at 3 years (p ≤ 0.001 versus baseline
for all) [20,42-47]. The once weekly exenatide formula-
tion has resulted in HbA1c reductions in the range of
-1.9% after 30 weeks of therapy [48]. Liraglutide has also
shown positive effects on glucose control and reductions
in HbA1c ranging from -0.6% to -1.5% over 14 to 52
weeks of therapy, respectively [43,49-52].
Dipeptidyl peptidase-4 inhibitors
DPP-4 inhibitors prolong the therapeutic activity of
GLP-1 by slowing its metabolism, leading to stimulation
of glucose-dependent insulin secretion and inhibition of
glucagon secretion. Sitagliptin, the first US FDA-
approved DPP-4 inhibitor, has been shown to release up
to 80% of DDP-4 activity after oral administration
[20,53,54]. The two DDP-4 inhibitors currently available
for oral administration are sitagliptin and saxagliptin.
Both agents are effective as monotherapy or in combina-
tion with other classes and reduce HbA1c by approxi-
mately -0.8% [20,55-57].
Amylin agonists
Pramlintide is an amylin analog that mimics the action
of native amylin, a hormone co-secreted with insulin,
and regulates glucose influx through the suppression of
glucagon and slowing of gastric emptying. Pramlintide is
an injectable agent used in patients who fail to achieve
treatment goals on prandial insulin. Treatment with
pramlintide has been shown to reduce HbA1c by up to
-0.6%, as well as prandial insulin requirements [20].
a-Glucosidase inhibitors
a-Glucosidase inhibitors suppress glucose levels by
reducing the absorption of carbohydrates from the gas-
trointestinal tract. They are approved as monotherapy
or in combination with SFUs and reduce HbA1c by
-0.6% to -1.3% [20].
The Effects of Antidiabetes Agents on Weight
Many of the available oral antidiabetes agents, as well as
insulin, are associated with weight gain that contribute
Table 3 Therapeutic considerations of selected US FDA-approved antidiabetes agents [20,21,25,30-35]
Intervention HbA1c
Reduction
(%)
Effect on
Weight
Effect on Lipids Effect on Blood
Pressure
Safety
Oral
SFUs 0.9-2.5 Increased Small
improvements;
mainly in TG
Poorly quantified Increased risk of hypoglycemia
Metformin 1.1-3.0 Neutral or
slightly
decreased
Improved Neutral Contraindicated in patients with renal insufficiency
Glinides 0.4-0.6 Neutral
(poorly
quantified)
Poorly quantified Poorly quantified Caution in patients with hepatic or renal impairment
(nateglinide)
TZDs 1.5-1.6 Increased Improved HDL
and TG
Small
improvements
Fluid retention, CHF, bone fractures, potential increase in MI
(rosiglitazone)
DPP-4
inhibitors
0.8 Neutral Poorly quantified Small
improvements in
non-diabetics
Long-term safety not established
a-
Glucosidase
inhibitors
0.5-1.0 Suggested
decrease
Poorly quantified Poorly quantified Frequent flatulence
Parenteral
Insulin Up to 4.9 Increased Improved Neutral Increased risk of hypoglycemia
GLP-1
receptor
agonists
0.8-1.5 Decreased Improved Lowered Nausea and vomiting; hypoglycemia with sulfonylureas; rare
pancreatitis and renal dysfunction; thyroid C-cell tumors in
rodents
Amylin
analog
0.4-0.6 Slightly
decreased
Small
improvements
Small
improvements
Contraindicated in patients with gastroparesis
BID, twice daily; CHF, congestive heart failure; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon like peptide-1; HbA1c, glycated hemoglobin; HDL, high-density
lipoprotein; MI, myocardial infarction; SFUs, sulfonylureas; TG, triglyceride; TZDs, thiazolidinediones; US FDA, United States Food and Drug Administration.
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[20,25] thereby creating a significant challenge in the
management of overweight/obese patients with type 2
diabetes.
Sulfonylureas/insulin
In UKPDS 33, intensive therapy with either SFUs or
insulin was associated with significant weight gain com-
pared with patients managed with diet alone (+3.1 kg,
p < 0.0001). Patients with type 2 diabetes treated with
insulin experienced the greatest increases in body weight
(+4.0 kg [p < 0.0001]), followed by chlorpropamide (+2.6
kg [p < 0.001]), and glibenclamide (+1.7 kg [p < 0.001])
when compared with conventional therapy [27].
Thiazolidinediones
TZDs have also been associated with weight gain and
edema, which has been shown to increase the risk for
heart failure. The weight gain associated with TZD therapy
is dose-dependent and more dramatic when used in com-
bination with insulin [20,58]. In more than 1,800 patients
s t u d i e do v e r1 6t o2 6w e e k s ,p ioglitazone monotherapy
was associated with increases of +0.9 to +2.6 kg as doses
were uptitrated from 15-45 mg and increases of +2.3
to +4.1 kg in combination with insulin across the same
dosing range in patients with type 2 diabetes [58,59]. At
doses of 4 and 8 mg, rosiglitazone increases body weight
by +1.0 to +3.1 kg when administered as monotherapy
and by +4.1 to +5.4 kg when administered with insulin
over 6-12 months [58,60].
Biguanides
MET therapy is weight neutral in patients with type 2
diabetes and may limit the weight gain experienced with
SFU, TZD, or insulin therapy [20,61]. Treatment with
MET therapy reported no weight gain when combined
with SFUs [62] and slight nonsignificant weight loss
when administered as monotherapy (change in BMI,
-0.7 kg/m
2 over 1 year of therapy) [41]. In 1 study invol-
ving 66 patients, MET, in combination with insulin, led
to a weight increase of +1.4 kg over 6 months compared
with increases of +3.6, +4.6, and +2.9 kg when insulin
was administered as monotherapy, in combination with
rosiglitazone, or with acarbose, respectively [61].
Dipeptidyl peptidase-4 inhibitors
The DDP-4 inhibitors are generally considered weight
neutral. Sitagliptin and saxagliptin have been associated
with weight reductions ranging from -0.1 to -1.2 kg over
24-30 weeks of monotherapy [55,57,63-65].
Glucagon like peptide-1 receptor agonists
The GLP-1 receptor agonists have been associated with
weight loss in patients with type 2 diabetes [25]. Exena-
tide results in progressive, dose-dependant weight loss
in patients with type 2 diabetes ranging from -2.8 to
-5.3 kg from baseline without a plateau in effect over 3
years of therapy (n = 217, p < 0.0001 at 3 years)
[25,31,44,46,66,67], with smaller reductions of -0.8 kg in
as early as 2 weeks [68]. At 3 years of follow-up,
patients with a baseline BMI < 30 kg/m
2 (n = 63) had a
reduction of body weight with exenatide of -3.9 kg from
baseline (p < 0.0001), and in patients with baseline BMI
≥ 30 kg/m
2 (n = 154), exenatide resulted in a weight
change of -5.8 kg (p < 0.0001) [45]. Exenatide once
weekly results in weight loss of approximately -4.0 kg
after 30 weeks, and 75% of patients lost weight [49]. Lir-
aglutide resulted in dose-dependent decreases in body
weight ranging from -1.0 to -3.2 kg in more than 1,300
patients with type 2 diabetes treated over 26 weeks
[43,51,52].
Amylin agonists
Treatment with the amylin analog pramlintide is asso-
ciated with improved weight control in patients with
type 2 diabetes when administered with insulin therapy
[20,32,69]. In a post hoc analysis of 2 studies in patients
with type 2 diabetes, pramlintide (n = 254) or placebo
(n = 244) was added to insulin therapy. Therapy with
pramlintide resulted in progressive reductions in body
weight starting at 2 weeks and a placebo-corrected
weight loss of -1.8 kg at 26 weeks (p < 0.0001). Weight
loss was most pronounced in patients with a baseline
BMI >40 kg/m
2 (-3.2 kg) [70].
Glinides and a-glucosidase inhibitors
The effects of glinides and a-glucosidase inhibitors on
weight have been poorly quantified in patients with type
2 diabetes. In a study of 248 patients (124 patients trea-
ted with MET/nateglinide and 124 with MET/glibencla-
mide) results suggest that the glinide class is weight
neutral with no change in BMI occurring over 12
months of therapy in patients treated with nateglinide
(+0.4 kg/m
2) or glibenclamide (+0.4 kg/m
2)[ 3 0 ] .
A Cochrane review of 681 patients summarized the
effects of the a-glucosidase inhibitor acarbose on
weight, reporting a -1.2 kg weight loss in patients with
IFG and/or IGT compared with placebo therapy [35].
The Effects of Antidiabetes Agents on Other CVD-
associated Risk Factors
Patients with type 2 diabetes commonly have decreased
H D L - C ,i n c r e a s e dT G s ,n o r m a lo rs l i g h t l ye l e v a t e dl o w -
density lipoprotein cholesterol (LDL-C), and hyperten-
sion, all of which contribute to the increased CV risk
seen in this patient population. Current guidelines for
type 2 diabetes and CVD prevention recognize the
importance of aggressively managing these risk factors
to minimize the risk of their complications [71-73].
Furthermore, the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) consider patients with type
2 diabetes as a CHD risk equivalent to patients with
documented CHD and recommend achieving the most
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for a goal of < 70 mg/dL in very high-risk patients
[10,74]. Most of the available antidiabetes agents
decrease hyperglycemia but are not associated with sig-
nificant improvement in BP and dyslipidemia in patients
with type 2 diabetes (table 3). Therefore, multiple medi-
cations to address both dyslipidemia and hypertension
m a yb er e q u i r e d .H o w e v e r ,B Pc o n t r o lm a yb eac h a l -
lenge in patients with type 2 diabetes and often requires
combination therapy to achieve goals [72].
Sulfonylureas
SFUs have been shown to reduce fasting and postpran-
dial TGs, but their effects on other lipid parameters,
particularly HDL-C, are inconsistent with some studies
showing an increase and others demonstrating a neutral
effect [36]. Glimepiride showed minimal changes to
lipid parameters during a 12-month study in treatment-
naïve patients with type 2 diabetes (total cholesterol
[TC], -0.19 mmol/L; HDL-C, -0.01 mmol/L, TG, -0.05
mmol/L) [41]. Likewise, the effects on BP have been
poorly quantified, with data coming from several small,
poorly controlled trials (total sulfonylurea group < 150
patients) and results ranging from neutral effects to sig-
nificant increases in BP during treatment with glyburide
or glipizide [72]. Over 12 months, glimepiride was asso-
ciated with small, nonsignificant decreases in SBP (-4.1
mm Hg) and DBP (-4.8 mm Hg) [41]. SFUs generally
are not considered to have anti-inflammatory and anti-
atherogenic properties. However, gliclazide has demon-
strated antioxidant activity which may lead to a small
improvement in coagulation, fibrinolysis, and monocyte
adhesion to endothelial cells [75,76]. Gliclazide has also
been shown to reduce levels of serum intercellular adhe-
sion molecules-1 (ICAM-1) [75]. In a small trial, glime-
piride use has resulted in a significant reduction in the
levels of tumor necrosis factor-a (TNF-a), interleukin-6
(IL-6), and hs-CRP [77]. Additional studies are needed
to define the clinical significance of these findings.
Glinides
Clinical trials of patients with type 2 diabetes treated
with glinides have shown no significant change in lipids
or BP parameters [36]. A recently published, rando-
mized, double-blind study of nateglinide and glibencla-
mide, in combination with MET, confirmed previous
findings [30]. In 119 patients treated with nateglinide
over 12 months, there were no significant changes in
LDL-C, HDL-C, TGs, SBP, or DBP compared with base-
line or SFU therapy at any time point during follow-up
[30]. Repaglinide has been reported to have a favorable
effect on markers of CV inflammation. IL-6, hs-CRP,
and serum ICAM-1 levels have been reported to be
reduced in association with repaglinide therapy [78-80].
In addition, endothelial function has been improved
[78]. Finally, a randomized trial compared repaglinide
with glyburide on carotid intima-media thickness (IMT)
after 12 months of therapy. Repaglinide-treated subjects
had significantly more frequent regression of IMT than
those treated with glyburide (p < 0.01) [81].
Biguanides
MET is associated with improvements in lipoprotein
metabolism, including decreases in LDL-C, fasting and
postprandial TGs, and free fatty acids [20,36]. A meta-
analysis of randomized, controlled, clinical trials found
that MET lowered BP (SBP and DBP), TGs, TC, and
LDL-C, and increased HDL-C from baseline. However,
many of these changes did not remain significant when
compared with control groups. Data from 37 trials
(N = 2,891) were analyzed on the effects of MET on
TGs. MET therapy was associated with a reduction of
-0.19 mmol/L in TGs, which was significant when com-
pared with the control groups (p = 0.003). Effects on
TGs were not affected by baseline BMI [82]. The meta-
analysis also found that MET was associated with a non-
significant increase in HDL-C of +0.01 mmol/L [82], but
a significant reduction in LDL-C was reported when
compared with controls (-0.22 mmol/L, p < 0.00001)
[82]. Data on the effects of MET on BP are variable
with studies reporting neutral effects or small decreases
in SBP and DBP [72]. Meta-analyses of randomized,
controlled clinical trials included 21 trials (n = 1,667)
reporting on SBP and 19 trials (n = 1,609) reporting on
DBP. Overall, SBP was reduced -1.78 mmHg and DBP -
0.57 mmHg; neither reduction was significantly different
from the control therapy, even at the highest MET
doses [82].
One report with MET has shown a significant effect
on a marker of fibrinolysis. In 27 patients treated with
MET, titrated up to a dosage of 850 mg three times a
day over 12 weeks, plasminogen activator inhibitor-1
(PAI-1) activity significantly fell compared with placebo
(p = 0.001) [83]. In a trial dealing with inflammatory
markers, patients treated with MET and a TZD (piogli-
tazone or rosiglitazone) for 12 months had significant
reductions of hs-CRP (p < 0.05) in association with
reduced insulin resistance [84]. However, a recent study
[85] evaluated the effects of initiating insulin glargine or
MET or placebo on inflammatory markers in 500 sub-
jects with recently diagnosed (median time from diagno-
sis 2 years) type 2 diabetes. Levels of hs-CRP, TNF
receptor 2, and IL-6 were measured at baseline and
after 14 weeks of therapy. Neither insulin nor MET
reduced inflammatory marker levels as compared with
the placebo groups, and there was no consistent associa-
tion found between glucose reduction and improvement
of inflammatory status [85]. Finally, in 353 subjects with
type 2 diabetes, MET or placebo were added to ongoing
insulin therapy and their effects on endothelial function
and inflammatory markers were evaluated [86]. After
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ICAM-1 levels. However, MET did improve several mar-
kers of endothelial function including von Willebrand
factor, soluble vascular cell adhesion molecule-1, and
soluble E-selectin [86].
Thiazolidinediones
While differences may exist among the agents, TZDs are
associated with increases in HDL-C, TG reductions, and
a modest BP-lowering effect [20,36,72]. In an observa-
tional study of 1,170 patients with type 2 diabetes, pio-
glitazone was associated with significant changes in
LDL-C (3.3 versus 3.2 mmol/L, p < 0.001), TGs (2.4 ver-
sus 2.2 mmol/L, p = 0.0032), HDL-C (1.3 versus 1.4
mmol/L, p < 0.001), SBP (141.1 versus 137.0 mmHg,
p < 0.001), and DBP (82.7 versus 80.0 mmHg, p <
0.001) from baseline after 20 weeks of therapy [87].
A study of 56 patients with type 2 diabetes treated with
rosiglitazone (n = 35) or pioglitazone (n = 21) found
that both rosiglitazone and pioglitazone significantly
increased HDL-C levels (+4% and +2%, respectively, p <
0.01); however, rosiglitazone-associated increases (14%)
were significantly higher than those seen in the pioglita-
zone group (9%, p < 0.05). Additionally, pioglitazone
therapy resulted in significantly greater reductions in
TGs (-29% versus -5%, p < 0.01) while rosiglitazone was
associated with significant increases in LDL-C (+20%
v e r s u s+ 1 % ,p<0 . 0 5 )[ 3 9 ] .I nas m a l ls t u d yo f2 2n o n -
diabetic subjects, pioglitazone significantly reduced DBP
(83 versus 77 mmHg, p = 0.02) and TGs (1.5 versus 1.0,
p = 0.02) while rosiglitazone increased TC (4.7 versus
5.1 mmol/L, p = 0.047) and LDL-C levels (2.7 versus 3.1
mmol/L, p = 0.07) [88].
TZDs have shown beneficial effects on a number of
markers of CV risk. In the Insulin Resistance Interven-
tion after Stroke (IRIS) V study, the effects of pioglita-
zone over 20 weeks on levels of hs-CRP were studied in
1,170 subjects naïve to TZD therapy. A decrease of hs-
CRP levels from a mean baseline of 3.8 μMt o2 . 8μM
was significant (p < 0.01) and occurred in association
with improvement of HbA1c, BP, and serum lipids [87].
Miyazaki and DeFronzo (2008) studied rosiglitazone (n
= 35) and pioglitazone (n = 21) and their effects on adi-
pocytokines (TNF-a, leptin, and adiponectin) in patients
with type 2 diabetes treated for 12 weeks. Both drugs
significantly decreased TNF-a (p < 0.05) and increased
adiponectin levels (p < 0.01). Leptin levels did not
change with either agent [39]. These beneficial changes
were in association with a reduction of insulin resistance
and improved glycemic control.
The Pioneer study consisted of 192 subjects with type
2 diabetes who were enrolled in an open-label, 6-month
study of pioglitazone or glimepiride to assess the anti-
inflammatory and antiatherogenic effects of each agent.
Pioglitazone, but not glimepiride, significantly improved
hs-CRP levels (p < 0.05, as well as levels of monocyte
chemo-attractant protein-1 and matrix metalloprotei-
nases-9 (p < 0.05 for both). Also, pioglitazone caused
substantial regression of carotid IMT from baseline (p <
0.001) [89]. Finally, 3 recent articles have described the
beneficial effects of the TZDs including reductions of
hs-CRP, improved endothelial function, reduced procoa-
gulatory state, and clinical outcome trials showing
reduction of restenosis and reocclusion rates post percu-
taneous coronary intervention [90-92].
Insulin
While insulin is effective in decreasing fasting and post-
prandial TG levels, a systematic review of the effects of
insulin on HDL-C levels found variable results with clin-
ical studies reporting increases or a neutral effect [36].
In a study of 104 insulin-naïve patients receiving combi-
nation therapy of SFU and MET, the addition of insulin
resulted in reductions in TC (-4.4%), LDL-C (-1.4%) and
TG (-19.0%) with no change in HDL-C levels [93]. Insu-
lin secretion is thought to increase BP, although there is
little scientific evidence that insulin has deleterious
effects on BP parameters [72]. Two recent post hoc ana-
lyses (combined N = 2,065) reported nonsignificant
changes in both SBP (-0.3 to -0.5 mmHg) and DBP
(-0.5 to -0.9 mmHg) from baseline over approximately
6 months of insulin therapy [94,95].
As noted above, a recent study [85] evaluated the
effects of initiating insulin glargine or MET or placebo
on inflammatory markers in 500 subjects with recently
diagnosed (median time from diagnosis 2 years) type 2
diabetes. Neither insulin nor MET reduced inflamma-
tory marker levels as compared with the placebo groups,
and there was no consistent association found between
glucose reduction and improvement of inflammatory
status [85]. Similarly, the ability of insulin glargine to
reduce levels of hs-CRP and PAI-1 was evaluated in 40
subjects with type 2 diabetes inadequately controlled
with MET and SFU. After 24 weeks, insulin glargine
had no effect on levels of hs-CRP or PAI-1 [96].
Glucagon-like peptide-1 receptor agonists
Unlike most oral antidiabetes agents, exenatide has
shown beneficial effects on lipid profiles, including TC
and LDL [46,66,67,94,95]. After 16 weeks of exenatide
therapy in patients with type 2 diabetes, patients with
the metabolic syndrome experienced significant reduc-
tions in TC (-7.4 mg/dL, p < 0.001), TGs (-16.7 mg/dL,
p < 0.001), SBP (-2.6 mmHg, p < 0.01), and DBP (-1.2
mmHg, p < 0.03), as well as insignificant changes in
LDL-C (-2.8 mg/dL) and HDL-C (-1.4 mg/dL) [67]. In a
post hoc analysis of an open-label extension trial, 151
patients treated with exenatide for 3.5 years experienced
significant improvements in TGs (-12%, p = 0.0003), TC
(-5%, p = 0.0007), HDL-C (+24%, p < 0.0001), SBP (-2%,
p = 0.0063), and DBP (-4%, p < 0.0001) [46].
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were followed for 52 weeks. SBP decreased -6.2 mmHg
and DBP decreased -2.8 mmHg from a baseline of 128/
78 mmHg, p < 0.05 for both. In patients with SBP >130
mmHg, reductions of SBP and DBP were even greater
(-11.4 mmHg and -3.6 mmHg, respectively, p < 0.05 for
both). These BP changes appeared to be independent of
weight loss or concomitant BP medication changes.
Favorable improvements in serum lipid profiles were
also reported. TC decreased -7.9 mg/dL from baseline
of 170 mg/dL (CI: -13.7, -2.0), LDL-C decreased -2.2
mg/dL from a baseline of 89 mg/dL (CI: -6.9, 2.5), TG
d e c r e a s e d- 4 0m g / d Lf r o mab a s e l i n eo f1 9 7m g / d L
(CI: -62.8, -17.3), and HDL-C decreased -0.3 mg/dL
from a baseline of 44 mg/dL (CI: -1.9, 1.3) [97].
A recent study by Derosa and colleagues (2010) [98]
compared the effects of exenatide versus glibenclamide
on glycemic control, body weight, beta-cell function,
insulin resistance, and inflammatory state in 128
patients with type 2 diabetes. Patients were inadequately
controlled with MET and were randomized to exenatide
titrated to 10 μgs u b c u t a n e o u sB I Dor glibenclamide 5
mg three times a day for 12 months. Hs-CRP was signif-
icantly improved with exenatide (from a baseline of 1.9
mg/L to 1.5 mg/L) compared with glibenclamide (from
a baseline of 1.9 mg/L to 1.8 mg/L, [p < 0.05 versus
glibenclamide]). Resistin levels and levels of retinol bind-
ing protein-4 were decreased with exenatide and
increased with glibenclamide (p < 0.01 versus glibencla-
mide). These changes were associated with improve-
ments of glycemic control, insulin resistance, and
beta-cell function [98].
One study compared liraglutide 1.8 mg once a day (n
= 233) with exenatide 10 μg twice a day (n = 231) with
a follow-up of 26 weeks (Liraglutide Effect and Action
in Diabetes [LEAD-6]). Compared with exenatide, lira-
glutide significantly reduced TG (-0.41 versus -0.23
mmol/L, p < 0.04) and free fatty acids (-0.17 versus
-0.10 mmol/L, p < 0.001). There were no significant dif-
ferences between the 2 groups on the effects on TC
(-0.20 versus -0.09 mmol/L), LDL-C (-0.44 versus -0.40
mmol/L), or HDL-C (-0.04 versus -0.05 mmol/L) [43].
A second study compared liraglutide 1.2 mg per day
(n = 178) or 1.8 mg per day (n = 178) to placebo (n =
177) in patients with type 2 diabetes receiving MET and
rosiglitazone. Liraglutide 1.2 mg significantly reduced
LDL-C (-0.28 versus -0.10 mmol/L, p < 0.05), TG (-0.28
versus -0.13 mmol/L, p < 0.05), and free fatty acids
(-0.03 versus +0.02 mmol/L, p < 0.05) as compared with
placebo [52]. Liraglutide is also associated with reduc-
tions in SBP ranging from -2.1 to -6.7 mmHg and DBP
f r o m- 1 . 0 5t o- 2 . 3m m H go v e r2 6t o5 2w e e k so ft h e r -
apy [43,49,52].
Liraglutide’s effects on CV risk markers were evalu-
ated in 165 patients with type 2 diabetes on oral ther-
apy. Subjects were randomized to liraglutide or placebo
and followed for 14 weeks. Liraglutide resulted in a sig-
nificant decrease in PAI-1 levels (p = 0.045) with non-
significant reductions in hs-CRP. There were no
treatment effects on levels of adiponectin, leptin, IL-6,
or TNF-a [99].
Dipeptidyl peptidase-4 inhibitors
The effects of DDP-4 inhibitors on CV risk factors are
well documented. In a systematic review and meta-ana-
lysis of incretin therapy in patients with type 2 diabetes,
Amori et al (2007) summarized 13 trials reporting data
on body weight in patients receiving DDP-4 inhibitors.
The data showed that DDP-4 inhibitors produce a small
increase in weight when compared with placebo and
had a small but favorable effect when compared with
SFUs or TZDs [25]. Similarly, 14 trials evaluating the
effects of DPP-4 on lipid levels showed no consistent
effect but there was an overall favorable trend in levels
of TGs and HDL-C and LDL-C [25]. In a study of sita-
gliptin added to MET therapy, sitagliptin was associated
with reductions in TGs (-4.8%, p ≤ 0.05 versus placebo)
and increases in HDL-C (+4.3%), LDL-C (+11.4%), and
TC (+4.9%, p ≤ 0.05 versus placebo) over 26 weeks of
therapy in patients with type 2 diabetes [65]. Raz et al
(2008) showed that sitagliptin had no significant
between-group differences in fasting blood lipid levels
or body weight as compared with placebo in 521
patients with type 2 diabetes treated for 30 weeks [57].
In a study of 19 patients with mild to moderate hyper-
tension on stable antihypertensive medication and with-
out diabetes, sitagliptin produced small reductions in
24-hour SBP (-2.0 to -2.2 mmHg) and DBP (-1.6 to -1.8
mmHg) over 5 days of therapy, which were significantly
different from placebo (p < 0.05) [100].
Amylin agonists
The effects of amylin analogs on lipid parameters appear
to be modest and dose-dependent. In a 4-week study of
203 patients with type 2 diabetes currently receiving
insulin therapy, pramlintide was associated with reduc-
tions in TC (-4.7 to -10.5 mg/dL), LDL-C (-4.4 to -.75
mg/dL), and TG (-9.0 to -66.4 mg/dL), with the greatest
reductions seen when the dosage was increased from
120 to 240 mg/day. Minimal effects on HDL-C were
reported (-0.51 to -0.70 mg/dL) [69]. Although the data
are limited, clinical trials show that pramlintide is not
associated with increases in BP in patients with type 2
diabetes [32].
a-Glucosidase Inhibitors
A Cochrane review of the literature involving more than
600 patients in the literature reported small, nonsignificant
changes in TC (-0.13 mmol/L), LDL-C (-0.16 mmol/L),
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as SBP (0.03 mmHg) and DBP (-1.31 mmHg) [35].
A study in 132 subjects with IGT was randomized to pla-
cebo or acarbose with a mean follow-up of 3.9 years. A
significant reduction of the progression of carotid IMT
was observed in the acarbose arm at the end of follow-up
(p = 0.027). The annual progression of IMT was reduced
by 50% [101]. In the Study to Prevent Non-Insulin-
Dependent Mellitus (STOP-NIDDM), acarbose was found
to reduce the relative risk of developing any CV event
by 49% (p = 0.03) with an absolute risk reduction of
2.5% [102].
In summary, the SFUs, insulin, and TZDs are gener-
ally associated with weight gain. The glinides, and DPP-
4 inhibitors are weight neutral, MET is weight neutral
or is associated with some weight loss and the GLP-1
receptor agonists are associated with significant weight
reductions (the amylin analogs and the a-glucosidase
inhibitors less so). Insulin, the TZDs, MET, and the
GLP-1 receptor agonists show fairly robust effects on
lipid levels in patients with type 2 diabetes. The other
agents generally have neutral or insignificant effects.
Finally, most antidiabetes agents have shown small
improvements or are neutral with regard to effects on
BP while the GLP-1 receptor agonists have been shown
to have significant effects on SBP and DBP. It should
also be noted that while beneficial effects on CVD sur-
rogate end points have been reported, there are no data
demonstrating a reduction of the incidence of CVD end
points.
Conclusions
Overweight/obese patients with type 2 diabetes are at
increased risk for CVD. The majority of patients with
type 2 diabetes are overweight/obese, which contributes
to an even higher risk for CVD. Exacerbating this con-
cern is the fact many antidiabetes therapies are asso-
ciated with weight gain. It is of utmost importance that
a multidisciplinary approach be undertaken to aggres-
sively manage modifiable CV risk factors in patients
with type 2 diabetes to prevent the associated morbidity
and mortality that is highly prevalent.
All antidiabetes pharmacotherapies lower glucose;
however, the effects on modifiable CV risk factors, such
as lipid and BP parameters, vary greatly among agents.
W h i l es o m et h e r a p i e sm a yl e a dt os i g n i f i c a n tw e i g h t
gain, others may have a weight-neutral effect or result
in weight loss. Most antidiabetes agents do not have a
significant adverse effect on BP or lipid parameters.
GLP-1 receptor agonists lower HbA1c and body weight
and have shown beneficial effects on lipid and BP para-
meters. These factors should be taken into consideration
when selecting an individualized antidiabetes regimen.
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